

Special Issue

Advances in Uveal Melanoma

Message from the Guest Editors

Uveal melanoma (UM) is a rare form of melanoma, accounting for approximately 5% of all melanoma cases in the United States. Despite successful treatments of primary UM, up to 50% of UM patients subsequently develop systemic metastases, which spread predominantly to the liver. Over the last decade, major discoveries have been made in the field of UM, including the identification of GNAQ/11 mutations as driver mutations and BAP1 and SF3B1 mutations as epigenetic determinants. Advances in technology also resulted in two treatments being approved by the US FDA, namely T-cell engager, tebentafusp-tebn (Kimmtrak™), and percutaneous hepatic perfusion with HEPZATO KIT™ (melphalan for injection/hepatic delivery system). These approaches totally changed the landscape of treatment for metastatic uveal melanoma (MUM). In this Special Issue, we aim to envision the current status of our understanding of UM and discuss the future directions of translational research projects. We hope that this Special Issue will guide researchers in the field of UM to identify a curative approach for MUM patients.

Guest Editors

Prof. Dr. Takami Sato

Department of Medical Oncology, Sidney Kimmel Cancer Center,
Thomas Jefferson University, 1015 Walnut Street, 1024 Curtis Building,
Philadelphia, PA 19107, USA

Dr. Mizue Terai

Department of Medical Oncology, Sidney Kimmel Cancer Center,
Thomas Jefferson University, 1015 Walnut Street, 1015 Curtis Building,
Philadelphia, PA 19107, USA

Deadline for manuscript submissions

31 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/205756

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)